ECSP066548A - 4-anilino-3-quinolincarbonitrilos para el tratamiento de leucemia mielogena cronica - Google Patents

4-anilino-3-quinolincarbonitrilos para el tratamiento de leucemia mielogena cronica

Info

Publication number
ECSP066548A
ECSP066548A EC2006006548A ECSP066548A ECSP066548A EC SP066548 A ECSP066548 A EC SP066548A EC 2006006548 A EC2006006548 A EC 2006006548A EC SP066548 A ECSP066548 A EC SP066548A EC SP066548 A ECSP066548 A EC SP066548A
Authority
EC
Ecuador
Prior art keywords
treatment
ome
chronic
leukemia
quinolincarbonitrilos
Prior art date
Application number
EC2006006548A
Other languages
English (en)
Spanish (es)
Inventor
Frank Charles Boschelli
Kim Timothy Arndt
Jennifer Michele Golas
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34590192&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP066548(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of ECSP066548A publication Critical patent/ECSP066548A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EC2006006548A 2003-11-06 2006-05-05 4-anilino-3-quinolincarbonitrilos para el tratamiento de leucemia mielogena cronica ECSP066548A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51781903P 2003-11-06 2003-11-06

Publications (1)

Publication Number Publication Date
ECSP066548A true ECSP066548A (es) 2006-10-17

Family

ID=34590192

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006006548A ECSP066548A (es) 2003-11-06 2006-05-05 4-anilino-3-quinolincarbonitrilos para el tratamiento de leucemia mielogena cronica

Country Status (18)

Country Link
US (2) US7417148B2 (https=)
EP (1) EP1680119A1 (https=)
JP (1) JP2007533655A (https=)
KR (1) KR20060118461A (https=)
CN (1) CN1874776A (https=)
AU (1) AU2004289243B2 (https=)
BR (1) BRPI0416289A (https=)
CA (1) CA2543163A1 (https=)
CO (1) CO5690608A2 (https=)
CR (1) CR8350A (https=)
EC (1) ECSP066548A (https=)
IL (1) IL175424A0 (https=)
MX (1) MXPA06004744A (https=)
NO (1) NO20062255L (https=)
RU (1) RU2006113691A (https=)
SG (1) SG146681A1 (https=)
WO (1) WO2005046693A1 (https=)
ZA (1) ZA200603596B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1680119A1 (en) * 2003-11-06 2006-07-19 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml)
CN103705517A (zh) 2005-06-17 2014-04-09 得克萨斯大学体系董事会 Src激酶抑制剂对溶骨性病变的抑制
CN101252931A (zh) * 2005-06-24 2008-08-27 惠氏公司 用于治疗癌症的4-苯胺基-3-喹啉甲腈
US20080119463A1 (en) * 2006-11-16 2008-05-22 Wyeth 4-Anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (AML)
WO2008060283A1 (en) * 2006-11-16 2008-05-22 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (aml)
WO2008064004A2 (en) * 2006-11-16 2008-05-29 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (aml)
CA2964162C (en) * 2007-06-01 2019-12-31 Wyeth Llc Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles having mutation in the bcrabl gene
WO2013187967A1 (en) 2012-06-15 2013-12-19 Institute For Cancer Research D/B/A The Research Institute Of Fox Case Cancer Center ("Fox Chase Cancer Center") Sensitization of cancer cells to dna damage by inhibiting kinases essential for dna damage checkpoint control
JP6280546B2 (ja) 2012-06-26 2018-02-14 デル マー ファーマシューティカルズ ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法
WO2015123758A1 (en) 2014-02-20 2015-08-27 Apotex Inc. Bosutinib forms and preparation methods thereof
EP3246046A4 (en) 2015-01-13 2018-12-05 Kyoto University Agent for preventing and/or treating amyotrophic lateral sclerosis
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
EP3953450A1 (en) 2019-04-09 2022-02-16 Massachusetts Institute Of Technology A micro physiological model for neuronal and muscular diseases and disorders
WO2022053130A1 (en) 2020-09-09 2022-03-17 Sid Alex Group, S.R.O. Antago-mir-155 for treatment of v-src, c-src-tyrosine kinase-induced cancers

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
TWI275390B (en) 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
TW200423938A (en) * 2003-02-21 2004-11-16 Wyeth Corp 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic injury
EP1680119A1 (en) * 2003-11-06 2006-07-19 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml)

Also Published As

Publication number Publication date
US7919625B2 (en) 2011-04-05
NO20062255L (no) 2006-08-01
IL175424A0 (en) 2008-04-13
US20050101780A1 (en) 2005-05-12
BRPI0416289A (pt) 2007-01-23
US7417148B2 (en) 2008-08-26
SG146681A1 (en) 2008-10-30
MXPA06004744A (es) 2006-07-05
CA2543163A1 (en) 2005-05-26
EP1680119A1 (en) 2006-07-19
CN1874776A (zh) 2006-12-06
CO5690608A2 (es) 2006-10-31
CR8350A (es) 2006-10-06
US20100029677A1 (en) 2010-02-04
RU2006113691A (ru) 2007-12-20
ZA200603596B (en) 2009-12-30
AU2004289243A1 (en) 2005-05-26
AU2004289243B2 (en) 2010-07-22
KR20060118461A (ko) 2006-11-23
JP2007533655A (ja) 2007-11-22
WO2005046693A1 (en) 2005-05-26

Similar Documents

Publication Publication Date Title
ECSP066548A (es) 4-anilino-3-quinolincarbonitrilos para el tratamiento de leucemia mielogena cronica
UY27918A1 (es) Derivados de benzodioxol
ECSP056127A (es) Inhibidores de 3-quinasa de fosfatidil-inositol
UY26512A1 (es) Inhibidores no peptídicos de la unión celúlar dependiente de vla - 4 útiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias
GT200400092A (es) Preparacion y uso de derivados de alquilarilo para el tratamiento de la obesidad
AR048741A1 (es) Derivados de omega-carboxiaril difenil urea sustituida
ES2571779T3 (es) Inhibidores de cinasa a base de nicotinamida
UY26958A1 (es) Nuevos agentes anticolinérgicos que se pueden emplear como medicamentos así como procedimiento para su preparación
UY28135A1 (es) Derivados de pirimidina para el tratamiento de crecimiento celular anormal
CR10127A (es) Agente para la prevención o tratamiento de neuropatías (divisional exp. 7849)
DOP2001000170A (es) Derivados de tiofeno utiles como agentes anticancesoros
NO20054856D0 (no) 4-anilo-kinazolinderivater som antiproliferative midler
CY1107403T1 (el) Μια μεθοδος δια την παρασκευη υπερινδοπριλης,των αναλογων ενωσεων αυτης και των αλατων αυτων με χρησιμοποιηση ενδιαμεσων ενωσεων 2,5-διοξο-οξαζολιδινης
BRPI0409105A (pt) análogos de quinobenzoxazina substituìdos
MXPA05007341A (es) Derivados de 2-piperidona como agonistas de prostaglandina.
UY29312A1 (es) Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones
UY27685A1 (es) Indolil-urea derivados de tienopiridinas útiles como agentes antiangiogénicos, y procedimientos para su uso
ECSP055972A (es) 4-[(2,4-dicloro-5-metoxifenil)amino]-6-alcoxi-3-quinoclincarbonitrilos para el tratamiento de lesiones isquémicas
DE602005027213D1 (de) Neue imidazolidinderivate
MY136824A (en) Substituted benzoxazinones and uses thereof
UY27979A1 (es) Indoles sustituidos en posición 2,4
TW200600971A (en) Calixresorcinarene compounds, photoresist base materials, and compositions thereof
MY138466A (en) Aminoalkoxyndoles as 5-ht6-receptor ligands for the treatment of cns-disorders
AR041339A1 (es) Derivados de tiazolpirimidinona,proceso de preparacion y composiciones farmaceuticas que los contienen
TW200722433A (en) Phosphorus compounds, use thereof and flame retarding polyester fibers